HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parlux

This article was originally published in The Rose Sheet

Executive Summary

Second quarter sales are expected to be up 74% to approximately $39 mil.-$40 mil., bolstered by international rollout of Guess? and Maria Sharapova fragrances as well as new Paris Hilton scent, Just Me, firm announces Oct. 6. Company's Perry Ellis fragrance portfolio will be strengthened by the launch of Perry 18 next summer, Parlux adds. Firm also reiterates previously reported fiscal year sales guidance of $190 mil.-$210 mil. Parlux will release final Q2 results the first week in November...

You may also be interested in...



Parlux

Final second quarter results, originally expected the first week of November, will not be released until Nov. 11 due to a power outage in Parlux' Florida-based office and distribution facility caused by Hurricane Wilma, fragrance marketer announces Nov. 1. The company has resumed normal operations and expects to meet previous guidance and holiday commitments. Second quarter sales are expected to be up 74% to approximately $39 mil.-$40 mil., company reported Oct. 6 (1"The Rose Sheet" Oct. 10, 2005, In Brief). Firm anticipates restarting stock buyback program as the hurricane "unreasonably depressed" stock market price. Parlux markets scents including Guess? and Just Me by Paris Hilton...

Switzerland Provides Gateway Into Mainland Europe For BASF’s Hepacor

With the Swiss launch of its Non-Alcoholic Fatty Liver Disease supplement, BASF is looking to make inroads into continental Europe. 

Orchard’s Gene Therapy Under Fast-Track Review At EMA

A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.
UsernamePublicRestriction

Register

RS013419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel